The cannabis and cannabis-derived products market continues to grow with increasing legalization at the state level. However, laws and regulations can vary greatly from state to state, and the future outlook remains murky at the federal level. This conference will examine the present and proposed regulatory schemes and concerns for this unique industry that impacts many FDA regulated product categories. Experts from across the country and abroad will also discuss practical concerns for entities attempting to navigate this continually evolving legal environment.

Conference Highlights:

  • Updates on federal legislation, regulation, and enforcement
  • State-level developments in legalization and regulation implementation
  • Outlook for both medical marijuana and cannabinoid ingredients in foods, dietary supplements, and cosmetics

Keynote Address: Norman Birenbaum, Senior Public Health Advisor, FDA



Industry & Firms

  • +$300 for non-members


  • +$100 for non-members


  • +$100 for non-members


  • +$100 for non-members


  • students registration


CANNRA MEMBERS: Apply for waived registration fee. 

FDLI is committed to ensuring the 2023 conference is well attended by CANNRA members. Registration fees may be waived for CANNRA members.  If granted, virtual registration is complementary. FDLI staff will be in contact after your application is received. 


Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.



Sponsorship opportunities are available. Please let us know if you would like more information.


Premier Sponsor



Premier Sponsor


Gold Sponsor


Gold Sponsor


Gold Sponsor



Silver Sponsor


Silver Sponsor

Planning Committee

Steven Leslie (Staff Liaison), FDLI
Donald R. Becker, Turning Point Brands, Inc.
Bill Bookout, National Animal Supplement Council
Marshall A. Custer, Husch Blackwell LLP
T. Daniel Logan, Kleinfeld, Kaplan & Becker, LLP
William Garvin, Buchanan Ingersoll & Rooney PC
Kate W. Hardey, McGuireWoods LLP
Jensen Jose, Center for Science in the Public Interest
Andrew Kline, Perkins Coie LLP
Deborah Miran, DMiran Consulting
Eliza Muse, Alaska Department of Health and Social Services
Michele Nakata, Hawaii Department of Health
Heike Newman, University of Colorado
Evelina Norwinski, Arnold & Porter LLP
Daniel Charles Rubenstein, Steptoe & Johnson LLP
Shawn “Pepper” Roussel, Green Pepper Solutions
Nandakumara D. Sarma, U.S. Pharmacopeia
Frederick A. Stearns, Keller and Heckman
Brian Yagi, Johns Hopkins University

Call For Proposals

FDLI and the Conference Planning Committee thanks those who participated in the Call for Proposals earlier this year. The input received from industry stakeholders helps us plan a timely program. If you submitted a proposal, you will be notified of the status of your proposal in April.